Using Olaparib for Advanced Prostate Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the overall survival and clinical outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) who are treated with olaparib in a real-world clinical setting. It will analyze both retrospective and prospective data from multiple centers to identify predictive and prognostic factors associated with treatment outcomes. The study focuses specifically on patients with BRCA mutations, providing insights into the effectiveness of olaparib for this subgroup.

Why it matters

Who can join: the full rules

Inclusion Criteria:

BRCA mutant Metastatic castration-resistant prostate cancer patients treatment with olaparib in clinical practice

Exclusion Criteria:

Olaparib treatment in a clinical trial

Where it's running

• Sabrina Rossetti
  Naples, Italy Recruiting
• Orazio Caffo
  Trento, Italy Recruiting

Study contacts

• Study coordinator: Orazio Caffo, MD
• Email: orazio.caffo@apss.tn.it
• Phone: +390461902478

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing a new drug ETX-19477 for advanced solid tumors

  This study is testing a new drug called ETX-19477 to see if it can help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting at 14 sites Phase 1/2 858 Therapeutics, Inc. · Phoenix, Arizona and 13 other locations · NCT06395519

• SYN818 for advanced or metastatic solid tumors

  This Phase 1 study will test oral SYN818 in adults with advanced or metastatic solid tumors, including breast, ovarian, and prostate cancers, whose standard treatments have been exhausted.

  Recruiting at 2 sites Phase 1 Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · Zhengzhou, Henan and 1 other locations · NCT06666270

• Combining pembrolizumab with targeted radionuclide therapy for advanced prostate cancer

  This study is testing if combining pembrolizumab with a targeted radiation treatment can help men with advanced prostate cancer live longer and feel better after other treatments have stopped working.

  Recruiting Phase 2 University of California, San Francisco · San Francisco, California · NCT05766371

• Imaging study using FCH-PET-CT in men with prostate cancer and DNA repair gene mutations

  This study is testing if a new type of imaging called FCH-PET-CT can better find cancer spread in men with prostate cancer who have certain gene mutations compared to regular imaging methods.

  Recruiting Institute of Cancer Research, United Kingdom · London, Sutton, Surrey · NCT05097274

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.